ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 240 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eventide Asset Management | 359,000 | $16,560,670 | 0.28% |
| PIER 88 INVESTMENT PARTNERS LLC | 23,300 | $1,074,829 | 0.27% |
| HARBOR CAPITAL ADVISORS, INC. | 25,972 | $1,198,088 | 0.24% |
| PDT Partners, LLC | 33,229 | $1,532,854 | 0.21% |
| Baker Brothers Advisors | 783,059 | $36,122,512 | 0.21% |
| FEDERATED HERMES, INC. | 1,776,600 | $81,954,558 | 0.20% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 329,668 | $15,207,585 | 0.19% |
| Virtus ETF Advisers LLC | 6,860 | $316,452 | 0.19% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 148,644 | $6,856,948 | 0.19% |
| Hudson Bay Capital Management LP | 501,772 | $23,146,742 | 0.17% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 604,287 | $27,875,759 | 0.16% |
| Alkeon Capital Management | 1,943,815 | $89,668,186 | 0.16% |
| FRED ALGER MANAGEMENT, LLC | 656,105 | $30,266,124 | 0.16% |
| HighVista Strategies LLC | 7,326 | $337,948 | 0.16% |
| Bridgefront Capital, LLC | 5,702 | $263,033 | 0.14% |
| Corton Capital Inc. | 6,062 | $279,640 | 0.13% |
| Woodline Partners LP | 236,564 | $10,912,697 | 0.13% |
| GW&K Investment Management, LLC | 286,471 | $13,215 | 0.12% |
| ClearBridge Investments | 2,763,246 | $127,468,532 | 0.12% |
| SEVEN EIGHT CAPITAL, LP | 13,804 | $636,779 | 0.10% |
External links
This page lists ULTRAGENYX PHARMACEUTICAL IN's shareholders in Q2 2023. To view ULTRAGENYX PHARMACEUTICAL IN's shareholder history, click here.